Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
Vaxart, Inc. (NASDAQ: VXRT) announces a business update and financial results for the full year ending December 31, 2023. The senior management team will host a conference call on March 14, 2024, at 4:30 p.m. ET.
03/07/2024 - 08:00 AM
Conference call to begin at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2023 after the market close on Thursday, March 14, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET.
The conference call can be accessed using the following information:
Webcast: Click here Date: Thursday, March 14, 2024 – 4:30 p.m. ET Domestic: (877) 407-0832 International: (201) 689-8433 Conference ID: 13744368
Investors may submit written questions in advance of the conference call to ir@vaxart.com .
A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.
About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contacts
Vaxart Media Relations: Mark Herr Vaxart, Inc.mherr@vaxart.com (203) 517-8957Investor Relations: Andrew Blazier FINN PartnersIR@vaxart.com (646) 871-8486
When will Vaxart provide a business update and report financial results for the full year ended December 31, 2023?
Vaxart will provide a business update and report financial results on March 14, 2024, after the market close.
What is the date and time of the conference call hosted by Vaxart's senior management team?
The conference call will be held on March 14, 2024, at 4:30 p.m. ET.
How can investors access the conference call?
Investors can access the conference call via webcast or by calling (877) 407-0832 domestically or (201) 689-8433 internationally.
Where can investors submit written questions in advance of the conference call?
Investors can submit written questions in advance to ir@vaxart.com.
Where can a replay of the webcast be found after the conference call?
A replay of the webcast will be available on Vaxart's website at www.vaxart.com.
VXRT Rankings
#4907 Ranked by Stock Gains
VXRT Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
About VXRT
since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.